GuidesHormonesLast checked August 24, 2026No dosing

Human growth hormone: injecting it, or stimulating your own

Two routes to the same number, and they cancel each other out if you try both. What each one is, who uses it, and which are approved for anything in Canada.

Compounding rules in this area are actively contested, so check again before relying on any of it.

The two routes, and the loopWhy they don't combine
Route one: inject the hormoneSomatropin, recombinant GH
You injectGrowth hormone itselfThe finished molecule, held at a flat level your body never makes on its own.
→
The liver makesIGF-1, upThe thing that gets measured, because GH itself comes in pulses and is gone between them.
→
The brakeYour pituitary goes quietHigh IGF-1 tells the hypothalamus to stop sending GHRH and start sending somatostatin. Natural output falls by about 85%.
Route two: prompt your ownSecretagogues: GHRH analogues and ghrelin mimetics
You injectA signal, not the hormoneTesamorelin, sermorelin or CJC-1295 copy GHRH, the accelerator. Ipamorelin or MK-677 press the other switch, the ghrelin receptor.
→
Your pituitary releasesGH, in pulsesYour own, mostly overnight, with the feedback loop intact and a ceiling your body still sets.
→
Why they don't addA prod at a gland told to stopRun both and route one's brake is already on. The second thing does almost nothing, for its full cost and risk.
IGF-1 infusion suppresses natural GH secretion by roughly 85%, mostly by flattening the pulses. Run route one and route two has almost nothing left to work on.

Growth hormone is made in your pituitary and released in pulses, mostly during deep sleep. It drives tissue repair, lean mass, fat metabolism, bone density and skin. Output peaks in adolescence and falls steadily from your twenties, and by sixty most people produce a small fraction of what they once did.

That decline is the entire premise of this market, and it's a real decline. The question everything below turns on is whether reversing the number reverses what people attribute to it, and there are two fundamentally different ways of trying.

Read this before the rest: the two approaches don't combine.

You can inject growth hormone, or you can use a peptide to prompt your own pituitary to release more. People sometimes do both, reasoning that two inputs must beat one. They cancel out, and the reason is the feedback loop.

Injected GH raises IGF-1. Rising IGF-1 tells your hypothalamus to stop sending GHRH and to start sending somatostatin, the stop signal. Your pituitary goes quiet. Measured directly, raising IGF-1 suppresses natural GH output by roughly 85%, mostly by flattening the pulses.

So a secretagogue taken alongside injected GH is prodding a gland that's being actively told to shut up. You're paying for the second thing to do almost nothing, while stacking whatever risk it carries on top of the first. It's one or the other.

Approach one: injecting growth hormone

Somatropin, recombinant human growth hormone

This is the hormone itself, manufactured and injected. Not a signal or a prompt, the finished molecule, delivered directly. It works, in the sense that it unambiguously raises GH and IGF-1. Everything else about it is a question of what for, and at what cost.

The medical uses, which are real and well established

Somatropin is approved in Canada and the US for growth hormone deficiency in adults and children, several paediatric growth disorders (Turner syndrome, Prader-Willi, small-for-gestational-age children who don't catch up), HIV-associated wasting, and short bowel syndrome. In genuine deficiency it's transformative rather than incremental, because it's replacing something a body can't make.

Diagnosing adult deficiency is deliberately rigorous. It takes stimulation testing, not a single low reading, because GH is pulsatile and a random draw between pulses looks like deficiency in a healthy person. That distinction, a diagnosed deficiency versus an age-related decline everyone has, is the line the rest of this section sits on.

Why people use it without that diagnosis

The longevity case is that age-related decline is itself a deficiency, just a universal one, and that restoring youthful levels restores youthful tissue. It traces largely to a small 1990 study in older men that reported gains in lean mass and losses in fat. That paper launched an industry, and its own journal later published an editorial cautioning against exactly the use it was being cited for.

Alongside that, there are athletes and bodybuilders using it for recovery and body composition, and a broader group chasing sleep quality, skin, and the general sense of resilience that fades. Body composition does change. What's much less established is whether the things people actually want follow: feeling better, functioning better, living longer. There's a real counter-argument in the other direction, too. Lower IGF-1 signalling is associated with longer life across a number of species, which is an awkward fact for the longevity pitch.

The legal position is stricter than people expect

In the US, human growth hormone isn't a controlled substance. It sits outside that schedule entirely, which sounds permissive and isn't. It has its own dedicated provision instead: distributing HGH for any purpose other than an approved indication is a federal felony carrying up to five years, doubling for distribution to a minor.

The detail that surprises people: the FDA reads "distribution" as including writing the prescription. The ordinary off-label latitude that covers most of medicine doesn't apply here in the same way. That's the single biggest reason anti-aging clinics offer peptides instead. It isn't better evidence, it's a statute that doesn't name them.

Canada has no equivalent HGH-specific criminal provision, and somatropin is a prescription drug under the ordinary rules. Buying it online from outside that system is a different problem: the product is unverified, there's no recourse, and counterfeit GH is common enough that I'd treat it as the default assumption rather than the exception.

Approach two: prompting your own pituitary

Secretagogues: GHRH analogues and ghrelin mimetics

The rationale, stated fairly, because it's a good one

Rather than supplying the hormone, these send the signal that makes your pituitary release its own. The argument for it is sound in principle. Your release comes in natural pulses, mostly overnight, with the feedback loop intact, so there's a ceiling your body still controls. Injected GH overrides that and holds a flat level the system never sees naturally.

More physiological, self-limiting, and in principle safer. That's a mechanistic argument, and it's where most of these part company with the evidence. A good reason to expect something isn't the same as a demonstration that it happened.

There are two different switches, which is why some get sold in pairs

Your pituitary responds to two separate signals. GHRH, from the hypothalamus, is the accelerator. Ghrelin, the same hormone involved in hunger, acts on a different receptor and also triggers release, partly by suppressing the brake. They're independent inputs, so hitting both at once produces a larger pulse than either alone.

That's the whole logic behind "CJC-1295 + ipamorelin" being sold as a unit: one from each column. It's a sound piece of physiology. It's also the point at which two unapproved compounds become one unstudied combination.

GHRH analogues, the accelerator

Tesamorelin (Egrifta) Approved in Canada, for HIV lipodystrophy only

A stabilised GHRH analogue. It sends the same kind of signal your hypothalamus sends, prompting a natural pulse.

Who takes it: In its approved use, people with HIV-associated lipodystrophy, prescribed by an HIV specialist and usually covered because it's a genuine treatment for a genuine complication. Almost nobody gets Egrifta prescribed for body composition or training. It's expensive, the indication doesn't fit, and no Canadian or US physician is writing it for the gym. The tesamorelin bought from peptide vendors isn't Egrifta.

Status: Approved, for one thing. Health Canada issued a Notice of Compliance in April 2014, and the FDA approved it earlier. The indication is reducing excess visceral abdominal fat in HIV patients with lipodystrophy, based on two trials in 816 patients. It's not approved for weight loss, body composition, athletic performance or aging, in either country.

Sermorelin Not approved, compounding grey zone

The original of this class, and the shortest-acting. A brief signal that produces a single sharp pulse.

Who takes it: Largely superseded. Its half-life is minutes, so it needs frequent injection to do much, and CJC-1295 was built specifically to solve that. Some anti-aging clinics still offer it, partly because it once had an approval and so sounds more legitimate than the alternatives. It's rarely anyone's first choice now.

Status: It was approved as Geref, then withdrawn from the market for commercial reasons, not a safety finding. It's now supplied through US compounding pharmacies. Not an approved product in Canada.

CJC-1295 Not approved, compounding grey zone

A longer-acting GHRH analogue. The DAC version binds to albumin and persists for days rather than minutes.

Who takes it: The workhorse of US anti-aging clinics, almost always paired with ipamorelin. Two different things are sold under this name. WITH DAC lasts days, which is convenient, but it holds a signal meant to be pulsatile permanently on, and that's the main objection to it. WITHOUT DAC, also sold as mod-GRF 1-29, lasts minutes, needs frequent injection and preserves the pulse. People arguing about CJC-1295 online are often arguing about different drugs.

Status: Not approved anywhere. US compounding pharmacies supply it on prescription, but its standing on the FDA's 503A bulk substances lists is contested, and sources in 2026 place it in different categories. Nothing equivalent exists in Canada.

Ghrelin mimetics, the other switch

Ipamorelin Not approved, compounding grey zone

Not a GHRH analogue at all. It acts on the ghrelin receptor, the other switch that triggers a GH pulse.

Who takes it: The default in this class, and it displaced its predecessors on tolerability rather than potency. GHRP-6, GHRP-2 and hexarelin came first and are now largely abandoned. They also raised cortisol and prolactin and provoked severe hunger, which made them unpleasant and, for anything long-term, counterproductive. Ipamorelin is the selective one that mostly doesn't. If you see the older three offered, that's a vendor selling old stock, not a considered choice.

Status: Not approved anywhere. It was investigated as a real drug candidate and abandoned in development, so the pharmaceutical interest was genuine and it just didn't finish. Supplied by US compounding pharmacies, with 503A standing contested, same as CJC-1295. Not available in Canada.

MK-677 (ibutamoren) Rejected for compounding

The same receptor as ipamorelin, but orally active and very long-acting. A pill rather than an injection.

Who takes it: Taken almost entirely by people who won't inject, which is a real constraint and the whole basis of its popularity. It's sold openly as a 'research chemical' rather than through clinics. The two things that make people stop are the hunger, which is substantial, unlike ipamorelin, and the water retention, which is often mistaken for the muscle gain it was taken for.

Status: Not approved, and uniquely on this page, that's a considered no rather than silence. In October 2024 an FDA advisory committee examined it directly and voted 13 to 1 against allowing it to be compounded, naming fluid retention, raised blood glucose and congestive heart failure. Everything else here is merely unstudied. This one was looked at and refused, which tells you far more.

What tesamorelin proves about the whole category

I think this is the most useful thing on the page, even if tesamorelin itself is irrelevant to you. It's mechanistically the same class as sermorelin and CJC-1295, a GHRH analogue prompting your own pituitary. The difference isn't the mechanism, the molecule type, or anything intrinsic. The difference is that somebody ran the trials: 816 patients, a defined endpoint, a regulator that read the data.

So "it's only a peptide, it just nudges your own hormone" isn't a reason something can't be studied and approved. One of them was. The others haven't been, and that's a statement about evidence, not about the category.

The corollary cuts the other way too, and it's the part I most want to be clear about. Tesamorelin is approved for visceral fat in HIV-associated lipodystrophy. Not for aging, not for body composition in healthy adults, not for recovery, not for training. An approval for one indication isn't a general endorsement, and no Canadian or US physician is prescribing Egrifta for the gym. It doesn't fit the indication, and it's expensive enough that nobody would try.

Which leads to the thing that matters here: the tesamorelin people buy from peptide vendors isn't Egrifta. It's unregulated material with the same name. The approval belongs to a specific manufactured product that went through trials, and it doesn't transfer to a vial from a research-chemical site any more than a trial result does. So tesamorelin is on this page as an argument about what the category could be if it were studied, not as a green light on what's being sold.

One person's switch from six years of growth hormone to tesamorelin, with every IGF-1 draw, is the tesamorelin diary, drawn from a real record and rebuilt every night.

"But a clinic prescribed it"

People are prescribed CJC-1295, ipamorelin and sermorelin by licensed practitioners. In the US the route is 503A compounding, a real regulated channel, but an exemption from the approval process rather than a form of it. Canada is stricter, and Health Canada has named CJC-1295 and ipamorelin in its unauthorised-peptide warning. Either way, a prescription is a practitioner's decision, not a finding that anything was assessed. I've written the full picture up on its own page: how unapproved drugs get prescribed in Canada.

There's one tell worth recognising here specifically. If a clinic offers you secretagogues but won't prescribe growth hormone itself, that isn't a clinical judgement that the peptides are better, it's the statute. HGH carries a federal criminal provision covering exactly these uses, and the peptides don't. Legal exposure is making the choice, not evidence, and the evidence for the peptides is thinner than for the hormone. A clinic that explains it that honestly is worth more of your trust than one presenting it as the superior protocol.

Sermorelin causes particular confusion because it was once an approved drug, which makes it sound more legitimate than its shelf-mates. It was withdrawn commercially, and the version compounded today isn't the approved product any more than vendor tesamorelin is Egrifta.

Whichever route: the measurement problem

GH is released in pulses and is nearly undetectable between them, so a single blood draw tells you almost nothing. It's the same fact that makes diagnosing real deficiency require stimulation testing. What gets tracked instead is IGF-1, which is stable enough to measure. It's a downstream proxy, not the thing itself.

Practically, if you're on any of this, "is it doing anything?" is hard to answer from how you feel. The honest approach is a baseline IGF-1 before starting and a repeat after. Anyone prescribing this without measuring isn't running an experiment, and neither are you.

Everything on this page, in one table

WhatClassRouteIn Canada
SomatropinThe hormone itself. Overrides your own production entirely.Recombinant HGHInjectionApproved for deficiency and specific conditions, not aging
TesamorelinThe only approved secretagogue, but the vendor version isn't the approved product.GHRH analogueInjectionApproved for HIV lipodystrophy only, not weight loss or training
SermorelinLargely superseded. A minutes-long half-life meant frequent injections.GHRH analogueInjectionNot available
CJC-1295Long-acting. The DAC version holds a signal meant to be pulsatile.GHRH analogueInjectionNot approved
IpamorelinThe selective one, with little cortisol, prolactin or hunger. Abandoned in development.Ghrelin mimeticInjectionNot approved
MK-677Oral, long-acting, raises hunger. Explicitly rejected 13 to 1 for compounding.Ghrelin mimeticOralNot approved

Everything below the first row is either unapproved or approved only for something other than what it's usually taken for.

What the table adds up to

Read down that first column and the sorting isn't really by molecule. One is a genuine treatment for a genuine deficiency. One was studied properly and approved, for a condition you almost certainly don't have. The rest share a mechanism with those two and have no outcome data at all.

What separates them isn't the category. It's whether anyone ran the trial. Tesamorelin is the same class of molecule as sermorelin and CJC-1295, and the difference is 816 patients and a regulator who read the file. So "it's only a peptide" isn't a defence of the unstudied ones, and it isn't a criticism of the studied one either. It just isn't the relevant question.

Two things are worth carrying away. Whichever row you pick, pick one column. Injected hormone and secretagogues suppress each other, so taking both is paying for one of them to do very little. And measure IGF-1 before and after, because on a pulsatile hormone your own sense of whether it's working is close to worthless. Without a baseline you aren't running an experiment, you're running a subscription.

Selfsense

If you're on one of these, what's worth having is your own before-and-after across months rather than an impression. Selfsense logs what you took and when, and plots it against your own IGF-1 draws and measurements.

Open your record →

General information, not medical advice, and not a recommendation to use anything described here. Most of what's on this page isn't approved for the uses people seek it for. Growth hormone raises blood glucose, interacts with several conditions, and is contraindicated in active malignancy. This is a conversation for a physician who knows your history.